New drug flotetuzumab tested for tough blood cancers
NCT ID NCT04681105
First seen Feb 01, 2026 · Last updated May 02, 2026 · Updated 6 times
Summary
This early-stage trial tested the safety and best dose of flotetuzumab, a lab-made antibody, in 13 people with advanced blood cancers that had come back or stopped responding to treatment. The goal was to see if the drug could help control the disease by blocking cancer cell growth. The study focused on tracking side effects and any signs of remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.